Format

Send to

Choose Destination
Clin Endocrinol (Oxf). 2017 May;86(5):680-687. doi: 10.1111/cen.13303. Epub 2017 Feb 26.

Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial.

Author information

1
Department of Endocrine and Metabolic Diseases, People's Hospital of Kelamay, Kelamay, Xinjiang, China.
2
Department of Clinical Epidemiology, Children's Hospital of Fudan University, Shanghai, China.
3
Department of Epidemiology and Statistics, School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, China.
4
Georgia Prevention Institute, Georgia Health Sciences University, Georgia, USA.
5
Department of Pharmacal, People's Hospital of Kelamay, Kelamay, Xinjiang, China.

Abstract

OBJECTIVE:

Alpha-lipoic acid (ALA) has shown beneficial properties on diabetes and obesity. The aim of this study was to examine the effects of oral ALA on body weight in subjects with overweight or obese.

DESIGN:

Single-centre, randomized, double-blind, crossover controlled study.

PARTICIPANTS:

A total of 166 subjects of Chinese Han ethnicity with a BMI ≥25 kg/m2 were screened and 103 subjects fulfilled the study requirements, in terms of informed consent and participation to the study.

MEASUREMENTS:

The subjects were randomized (1:1) to receive either ALA (1200 mg/day) or placebo treatment in a crossover design for 8 weeks. The primary end-point was the change in body weight. The secondary end-points were the changes in waist circumference, BMI, lipid profile, plasma leptin levels and the adverse events that occurred following ALA treatment.

RESULTS:

The changes in the body weight and waist circumference noted in the ALA group were significantly different compared to the placebo group as demonstrated by mixed model statistical analysis (both P < 0·05). No real weight reduction was seen in the ALA group, and no significant differences were noted as regards cholesterol levels, triglyceride levels, high-density lipoprotein cholesterol levels and adverse events between the two groups. The administration of ALA was well tolerated, and no serious adverse events were noted.

CONCLUSIONS:

Oral administration of ALA (1200 mg/day) for 8 weeks induced mild weight loss accompanied by a reduction in waist circumference.

PMID:
28239907
DOI:
10.1111/cen.13303
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center